Abstract: Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Abstract: Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Abstract: Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Abstract: Provided is a method for improving secretion efficiency of a recombinant foreign protein in a yeast expression system. The method includes transforming a yeast host with a recombinant foreign gene construct containing a galactose-inducible promoter, a secretion signal sequence and a gene encoding the foreign protein to construct a transformed yeast strain; and culturing the transformed yeast strain under the condition that the activity of the galactose-inducible promoter is controlled. Improved secretion efficiency of the foreign protein can be achieved by decreasing overexpression-induced insoluble precipitation of the recombinant foreign protein suffered by a conventional galactose-inducible promoter-based yeast expression system, via appropriate control of a level of galactose functioning as an inducer of the galactose-inducible promoter in cells.
Abstract: Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFS) thereof and, more particularly, UL1, UL119 and RL6.
Abstract: The present invention relates to a method for mass production of a recombinant protein comprising the step of culturing a yeast transformed with: a recombinant gene construct comprising a yeast promoter, a gene coding a signal sequence and a gene coding a target protein; and also with one or more genes coding folding accessory protein selected from the group consisting of PDI1 (protein disulfide isomerase 1), SEC23 (secretory 23), TRX2 (thioredoxin 2) AHA1 (activator of heat shock protein 90 ATPase), and SCJ1 (S. cerevisiae DnaJ) followed by culturing the transformed yeast.
Type:
Application
Filed:
December 1, 2009
Publication date:
June 2, 2011
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Hyung Kwon LIM, Jin-Ho SEO, Yong-Cheol PARK
Abstract: Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
Abstract: A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.
Type:
Application
Filed:
July 7, 2008
Publication date:
January 13, 2011
Applicant:
Mogam Biotechnology Research Institute
Inventors:
Meehyein Kim, Duckhyang Shin, Hyeon Lee, Soo In Kim, Yeup Yoon
Abstract: The present invention relates to a method for preparing LK8 protein, more precisely, a method for mass-production of LK8 protein using Saccharomyces cerevisiae transformed by a gene coding LK8 protein having angiogenesis inhibiting activity. The transformed strain of the present invention and production processes of LK8 protein are expected to contribute greatly to the commercialization of LK8 protein as a novel angiogenesis inhibitor.
Type:
Grant
Filed:
January 26, 2005
Date of Patent:
December 28, 2010
Assignee:
Mogam Biotechnology Research Institute
Inventors:
Hyung-Kwon Lim, Jung Hwan Park, Sung-Geun Kim
Abstract: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
Type:
Application
Filed:
June 1, 2010
Publication date:
September 23, 2010
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Meehyein KIM, Soo In Kim, Duckhyang Shin, Mahnhoon Park
Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.
Abstract: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.
Type:
Application
Filed:
May 8, 2008
Publication date:
August 19, 2010
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Soo In Kim, Duckhyang Shin, Hyeon Lee, Meehyein Kim, Doo-Hong Park, Yeup Yoon
Abstract: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.
Type:
Application
Filed:
November 16, 2007
Publication date:
August 5, 2010
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Hyun-Kyung Yu, Yeup Yoon, Jin-Hyung Ahn, In-Hwan Lim, Ho-Jeong Lee, Jang-Seong Kim, Doo-Hong Park
Abstract: Provided is a method for improving secretion efficiency of a recombinant foreign protein in a yeast expression system. The method comprises transforming a yeast host with a recombinant foreign gene construct comprising a galactose-inducible promoter, a secretion signal sequence and a gene encoding the foreign protein to construct a transformed yeast strain; and culturing the transformed yeast strain under the condition that the activity of the galactose-inducible promoter is controlled. Improved secretion efficiency of the foreign protein can be achieved by decreasing over-expression-induced insoluble precipitation of the recombinant foreign protein suffered by a conventional galactose-inducible promoter-based yeast expression system, via appropriate control of a level of galactose functioning as an inducer of the galactose-inducible promoter in cells.
Abstract: The present invention relates to detoxified and immunologically active proteins (“mutant LTs”) having mutated amino acid sequences of heat-labile enterotoxin of E. coli, DNA sequences encoding the mutant LTs, recombinant expression vectors comprising the DNAs, recombinant microorganisms transformed with the recombinant expression vectors, process for preparing the mutant LTs and pharmaceutical application of the said protein as immunogenic antigens for vaccination and as adjuvants for anti-body production. In contrast to wild-type LT, the mutant LTs did not induce any toxic activities. The mutant LTs elicited high and comparable levels of anti-LT antibodies when delivered either intragastrically or intranasally, inducing systemic and local responses in serum and fecal extracts. Thus, they might be useful for the development of a novel diarrheal vaccine in humans and animals.
Type:
Grant
Filed:
September 15, 1999
Date of Patent:
May 25, 2010
Assignee:
Mogam Biotechnology Research Institute
Inventors:
Eun Jeong Park, Jang Seong Kim, Jihoon Chang, Jungsun Yum, Soo-il Chung
Abstract: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.
Type:
Application
Filed:
August 20, 2009
Publication date:
March 11, 2010
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Meehyein KIM, Duckhyang Shin, Soo In Kim, Mahnhoon Park
Abstract: The present invention relates to a method for reducing the fucose content of a recombinant protein, which comprises expressing in an animal cell the recombinant protein and FUCA1, an FUCA1 mutant, FUCA2, or a fragment of FUT8 localization domain; or with a fusion protein of a fragment of FUT8 localization domain and a fragment of FUCA1, a FUCA1 mutant or FUCA2. Therefore, the antibody expressed according to the method of the present invention exhibits a reduced fucose content in their Fc regions, which leads to the improvement in the therapeutic effect thereof.
Type:
Application
Filed:
January 9, 2009
Publication date:
January 7, 2010
Applicant:
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
Inventors:
Jung-Seob KIM, Jae-Hoon MOON, Mee Sook OH, Kong Ju LEE, Yeup YOON
Abstract: The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV protein expression and replication. The method of the invention, which includes the step of administrating the synthetic siRNA or a DNA vector encoding the RNA, is thus effective for the treatment of HCV carrier by inhibiting HCV gene expression and replication.
Type:
Application
Filed:
May 30, 2006
Publication date:
December 24, 2009
Applicant:
Mogam Biotechnology Research Institute
Inventors:
Meehyein Kim, Duckhyang Shin, Mahnhoon Park, Soo In Kim
Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.
Abstract: The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human ?-globin 5? MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.
Type:
Grant
Filed:
July 27, 2001
Date of Patent:
September 9, 2008
Assignees:
Mogam Biotechnology Research Institute, Neurotech Pharmaceuticals Co., Ltd.
Inventors:
Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon